ApoE4-targeted therapeutics that normalize SirT1

使 SirT1 正常化的 ApoE4 靶向疗法

基本信息

  • 批准号:
    9914435
  • 负责人:
  • 金额:
    $ 29.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT / SUMMARY ABSTRACT Our studies link for the first time the major risk factor for Alzheimer's disease - ApoE4 - with major longevity determinants, the Sirtuins; and identify the first candidate therapeutics that target this new link. Alzheimer's disease (AD) currently afflicts more than 5.4 million people in the US at an estimated cost to society of greater than $200 billion per year. The currently approved drugs for AD provide only short-term symptomatic relief but do not alter disease progression. The dominant risk factor for Alzheimer's disease (AD) is the epsilon-4 (ε4) allele of apolipoprotein E (ApoE4), which is present in about two-thirds of AD patients. The ApoE4 allele (chromosomal locus 19q13) confers increased risk for sporadic and late-onset AD (LOAD). Despite over a decade of knowledge that the ApoE4 allele is somehow contributory to the disease process, the precise molecular mechanisms underlying ApoE4-associated AD risk remain unclear. Our studies shed light on a novel mechanism for ApoE4-mediated toxicity and revealed a key mediator − SirT1 − that is differentially affected by ApoE4 vs. ApoE3. Interestingly, while both ApoE3 and ApoE4 bind to APP, only ApoE4 associates with nanomolar affinity (Kd ~80nM), and only ApoE4 significantly: (a) reduces the ratio of sAPPα to Aβ; (b) reduces SirT1 expression, resulting in a marked reduction of SirT1 levels and in the ratio of neuroprotective SirT1 to neurotoxic SirT2; (c) triggers tau and APP phosphorylation; and (d) induces programmed cell death. In our initial screen of a clinical library we have identified a promising hit (A03) that is a repurposing candidate, is highly brain permeable, and reverses the reduction of SirT1 levels. As part of this proposal we plan to complete the preclinical testing of A03 and develop new chemical entity (NCE) analogs of A03 for further development. In addition, through screening and “hit-to-lead” optimization we plan to discover new lead candidates for further testing. The eventual goal of the proposal is to provide 1-2 candidates for non-GLP toxicity testing. Our data support the hypothesis that neuronal connectivity - influenced by the ratios of critical mediators including sAPPα:Aβ, SirT2:SirT1, APP:p-APP, and tau:p-tau - is programmatically altered by ApoE4. The collaboration with the Clinical Core and the Gylys lab is important in this project, as it would provide preliminary analysis of plasma and CSF samples from ApoE genotyped patients for levels of SirT1. Such data would be extremely useful for future development of ApoE4-targeted drug candidates to clinical testing and SirT1 as a potential plasma biomarker in MCI/AD. In addition, comparing SirT1 with other biomarkers in plasma/CSF that are affected by the sirtuin/NFkB signaling is planned and would help further elucidate the role of ApoE4 in AD. The overall primary objective of this project is to identify potent, orally active, brain permeable SirT1-enhancing lead candidates that are suitable for further preclinical IND development as the first ApoE4- targeted SirT1 therapeutics for AD and to development the tools necessary to ascertain target engagement and efficacy.
项目/摘要 我们的研究首次将阿尔茨海默病的主要危险因素-ApoE 4-与阿尔茨海默病的主要危险因素联系起来。 长寿的决定因素,Sirtuins;并确定第一个候选疗法,针对这一新的联系。 阿尔茨海默病(AD)目前在美国折磨着超过540万人,估计花费为 每年超过2000亿美元。目前批准的AD药物仅提供短期的 症状缓解但不改变疾病进展。阿尔茨海默病(AD)的主要危险因素 是载脂蛋白E(ApoE 4)的ε4等位基因,约三分之二的AD患者中存在。的 ApoE 4等位基因(染色体位点19 q13)增加了散发性和迟发型AD(LOAD)的风险。 尽管十多年来人们都知道ApoE 4等位基因在某种程度上对疾病过程有贡献, ApoE 4相关AD风险的确切分子机制仍不清楚。我们的研究揭示了 ApoE 4介导的毒性的新机制,并揭示了一个关键的介质-SirT 1-, 受ApoE 4和ApoE 3影响。有趣的是,虽然ApoE 3和ApoE 4都与APP结合,但只有ApoE 4与APP结合。 具有纳摩尔亲和力(Kd ~ 80 nM),只有ApoE 4显著:(a)降低sAPPα与Aβ的比值;(B) 降低SirT 1表达,导致SirT 1水平和神经保护性细胞比率显著降低。 SirT 1转化为神经毒性SirT 2;(c)触发tau和APP磷酸化;和(d)诱导程序性细胞死亡。 在我们对临床文库的初步筛选中,我们已经鉴定出一个有希望的命中(A03),它是一个再利用的候选者, 具有高度的脑渗透性,并逆转SirT 1水平的降低。作为该提案的一部分,我们计划 完成A03的临床前测试,并开发A03的新化学实体(NCE)类似物, 发展此外,通过筛选和“点击到铅”优化,我们计划发现新的铅 候选人进行进一步测试。该提案的最终目标是为非GLP提供1-2个候选人 毒性测试我们的数据支持神经元连接性的假设--受关键神经元的比率的影响。 包括sAPPα:Aβ、SirT 2:SirT 1、APP:p-APP和tau:p-tau在内的介导物被ApoE 4以编程方式改变。 与临床核心和Gylys实验室的合作在这个项目中很重要,因为它将提供 对ApoE基因分型患者的血浆和CSF样品进行SirT 1水平的初步分析。这样的数据 对于将来开发ApoE 4靶向药物候选物进行临床测试将是非常有用的, SirT 1作为MCI/AD的潜在血浆生物标志物此外,将SirT 1与其他生物标志物进行比较, 血浆/CSF受sirtuin/NFkB信号转导的影响,这将有助于进一步阐明 AD中ApoE 4的表达。该项目的总体主要目标是确定有效的,口服活性,脑渗透 SirT 1增强型先导候选药物,适合作为第一个ApoE 4- 针对AD的靶向SirT 1疗法,并开发确定靶点参与所需的工具 和功效。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Varghese John其他文献

Varghese John的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Varghese John', 18)}}的其他基金

Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules
使用脑通透性小分子评估 sAPPalpha 的 p-Tau 抑制和神经保护作用
  • 批准号:
    10522638
  • 财政年份:
    2022
  • 资助金额:
    $ 29.79万
  • 项目类别:
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels
筛选降低细胞内 α-突触核蛋白水平的化合物
  • 批准号:
    10218979
  • 财政年份:
    2021
  • 资助金额:
    $ 29.79万
  • 项目类别:
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD
护脑素小分子模拟物可使神经元 p-Akt 正常化,作为 AD 的新型疗法
  • 批准号:
    10810521
  • 财政年份:
    2021
  • 资助金额:
    $ 29.79万
  • 项目类别:
Screening for enhancers of secreted clusterin (sCLU) and evaluation in AD models
分泌型凝聚素 (sCLU) 增强子的筛选和 AD 模型的评估
  • 批准号:
    10195566
  • 财政年份:
    2021
  • 资助金额:
    $ 29.79万
  • 项目类别:
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD
护脑素小分子模拟物可使神经元 p-Akt 正常化,作为 AD 的新型疗法
  • 批准号:
    10211023
  • 财政年份:
    2021
  • 资助金额:
    $ 29.79万
  • 项目类别:
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels
筛选降低细胞内 α-突触核蛋白水平的化合物
  • 批准号:
    10524695
  • 财政年份:
    2021
  • 资助金额:
    $ 29.79万
  • 项目类别:
Screening for enhancers of sAPPalpha
筛选 sAPPalpha 增强子
  • 批准号:
    9038682
  • 财政年份:
    2016
  • 资助金额:
    $ 29.79万
  • 项目类别:
Screening for enhancers of sAPPalpha
筛选 sAPPalpha 增强子
  • 批准号:
    9265756
  • 财政年份:
    2016
  • 资助金额:
    $ 29.79万
  • 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
  • 批准号:
    8988211
  • 财政年份:
    2015
  • 资助金额:
    $ 29.79万
  • 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
  • 批准号:
    9231359
  • 财政年份:
    2015
  • 资助金额:
    $ 29.79万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.79万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了